European Commission logo
English English
CORDIS - EU research results

Deciphering the molecular mechanism(s) behind the evolution of Mycobacterium tuberculosis towards slow growth, and the impact on virulence and persistence

Project description

Slow-growing mycobacteria responsible for tuberculosis persistence

Tuberculosis remains a significant infectious disease worldwide with more than one million deaths every year. During its evolution, the causative agent Mycobacterium tuberculosis seems to have acquired a slow growth phenotype, which likely has contributed to the bacterium becoming a highly successful human pathogen. The EU-funded Slow growth project will decipher the molecular mechanisms responsible for this change in growth rate compared to ancestral mycobacteria. Using genetic manipulation of closely related, but faster growing Mycobacterium canettii variants and phenotypic assays, researchers will dissect the evolutionary events that led to such a change. Results will provide insight into mycobacterial virulence and persistence and pave the way for more effective strategies for the treatment of tuberculosis.


Tuberculosis (TB) is an infectious disease caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb), responsible for 1.5 million deaths per annum. Moreover, due to the ability of Mtb to persist in the host, a further one third of the world population is latently infected and at risk for disease later in life. So far, the major vaccine against TB (Bacille Calmette-Guérin vaccine) has a limited impact on the global TB epidemic, as it does not always prevent pulmonary infections in adults. Furthermore, drug resistant strains have emerged and spread worldwide, threatening to render the actual 6-month treatment ineffective. In this context, studying the molecular mechanisms underlying mycobacterial virulence and persistence are crucial to develop new strategies to treat TB.
A hallmark of Mtb is its slow growth rate. Recent phylogenetic studies have demonstrated that ancestral mycobacteria were first fast-growing bacteria, before an evolutionary separation into fast- and slow-growing mycobacteria. Intriguingly, all the main human mycobacterial pathogens, including Mtb, are slow-growers, suggesting the importance of slow-growth as a successful evolutionary step to become professional human pathogens. Using cutting-edge multidisciplinary approach, combining real-time single cell techniques and genetic approaches, I will, in collaboration with the Brosch lab, decipher the molecular mechanism(s) which led to the evolution of Mtb towards a slower growth, by taking advantage of the fast-growing M. canettii, closely related to the ancestor of Mtb and genetically tractable. I will also directly investigate the biological importance of slow growth on the virulence and persistence of Mtb by genetically engineering Mtb strains with different growth rates. Altogether, this work will lead to new perspectives and insights into host-Mtb interaction, important for the development of innovative therapeutic approaches.


Net EU contribution
€ 184 707,84
75724 Paris

See on map

Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Total cost
€ 184 707,84